FDA approves new dosing of Lilly’s Alzheimer’s drug Kisunla to lower brain...
Eli Lilly’s new Alzheimer’s drug is off to a slow start, but the Indianapolis drugmaker hopes that an update to the treatment’s prescription label may help build confidence among doctors and patients ...
View ArticleMerck to buy respiratory drugmaker Verona Pharma for $10B
Merck is boosting its respiratory portfolio with a $10 billion takeover of commercial-stage drugmaker Verona Pharma, the companies said Wednesday morning. It signals Merck’s ongoing appetite for large...
View ArticleAstraZeneca’s Alexion inks AAV capsid deal with JCR Pharma
AstraZeneca’s rare disease business Alexion returns to JCR Pharmaceuticals for another deal, this time for a pact worth up to $825 million for its adeno-associated virus capsids. Alexion will use JCR’s...
View ArticleRevolution and Iambic sign AI R&D deal for cancer drugs
Revolution Medicines has become one of the industry's most valuable pre-commercial companies thanks to its pipeline of clinical-stage cancer drugs. CEO Mark Goldsmith is pressing ahead on what could be...
View ArticleRhythm says oral rare obesity drug clears Phase 2 test, plans tweaks to...
Rhythm Pharmaceuticals said Wednesday its oral candidate for a rare form of obesity produced “statistically significant and clinically meaningful” reductions in BMI in a mid-stage trial. The biotech...
View ArticleTrump’s CDC nominee Monarez advances to full Senate
Susan Monarez's nomination for CDC director cleared the Senate health committee on Wednesday, putting her one step closer to leading the agency after an upheaval of its vaccine advisers. If confirmed...
View ArticleBiopharma pay analysis: Highest-paying drugmakers of 2024
The typical employee at a publicly traded life sciences company made $224,729 last year, according to an Endpoints News analysis of pay trends across the industry. Endpoints reviewed hundreds of annual...
View ArticleCoRegen closes $93M financing round to enter the clinic
Clinical-stage gene therapy biotech CoRegen has secured $93.4 million in a financing round to develop its manufacturing processes, fund its first clinical study and build up its leadership team. The...
View ArticleRetiring Arvinas CEO reflects on his time leading the PROTAC company
Arvinas CEO John Houston is planning to retire after more than eight years at the helm, the company announced Wednesday, as its lead protein degrader program approaches an inflection point. Arvinas has...
View ArticleJ&J prevails in schizophrenia drug patent spat against Teva
Johnson & Johnson beat back Teva's patent challenge in a federal appeals court ruling that closes out a yearslong fight over J&J’s antipsychotic medication Invega Sustenna. The US Court of...
View ArticleFederal judge sides with FDA on its mifepristone rules
The FDA acted within its purview when it maintained some safety requirements for the abortion pill mifepristone following an agency review, a federal court in Washington ruled. “The Court cannot find,...
View ArticleFDA’s pediatric adcomm votes to continue surveillance of 21 drugs, three...
The FDA’s pediatric advisory committee voted almost unanimously to continue monitoring 21 drugs and three vaccines for side effects, including blockbusters such as Novartis’ heart drug Entresto and...
View ArticleSwiss and German radiopharma biotech Nuclidium collects $99M Series B
For the second day in a row, a European radiopharma company said it has bagged a large venture funding round. Basel and Munich-based startup Nuclidium has pulled together a CHF 79 million (about $99...
View ArticleKidney health biotech Renasant Bio emerges with $54M to follow in Vertex’s...
A Berkeley, CA-based biotech that wants to replicate Vertex’s success with corrector and potentiator medicines has raised a $54.5 million seed round. The funding, disclosed Thursday morning, will help...
View ArticleUltragenyx, Mereo’s bone disease drug fails second interim analysis, stocks...
Ultragenyx Pharmaceutical and Mereo BioPharma’s antibody for a rare bone disease failed a second interim analysis in its pivotal trial, the companies revealed late on Wednesday. The study will continue...
View ArticleBiotech’s Q2 numbers paint a picture of the good, the bad and the ugly
The numbers aren’t all bad in biotech. But you’d be forgiven if you thought they were. And you’d be in good company. Once again, Chris Dokomajilar at DealForma has been checking the data for us ...
View ArticleEndpoints livestream: Curie.Bio CEO Zach Weinberg on China biotech competition
Today on Post-Hoc Live, we're talking about China — and how some in biotech want to make it harder for US companies to do deals there. The drug industry has turned to China for new molecules ...
View ArticleA state bill threatens to ban AI therapists, forcing health tech startups to...
AI therapists could soon be banned for the first time in the US under an Illinois bill, as mental health companies scramble to comply. The Wellness and Oversight for Psychological Resources Act forbids...
View ArticleDHL’s $700M+ expansion in UK and Ireland; Novo Nordisk’s quality testing site...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. DHL Supply Chain has invested £550 million ($748 million) to expand...
View ArticleSoleno's first wave of rare disease drug sales beats expectations
The first full quarter sales for Soleno Therapeutics’ rare disease drug Vykat XR are in, and they have exceeded investor forecasts. Soleno said Thursday morning that Vykat XR ...
View ArticleFor first time ever, FDA publishes drug rejection letters
In a historic first, the FDA on Thursday released about 200 novel and generic drug rejection letters, bucking the agency's former unwillingness to release the documents. But it's a small step ...
View ArticleAstraZeneca hands over opioid addiction pill to Eolas; TandemAI, Perpetual...
Plus, news about Pfizer and Astellas' Xtandi, BeOne Medicines, Biocytogen and Rhythm: Eolas Therapeutics takes opioid addiction pill from AstraZeneca: The biotech will assume full development rights ...
View Article